Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hyo-Soo Kim
Patients were randomly assigned to 2 groups: (1) Triple therapy (40mg of telmisartan and 5mg of amlodipine and 10mg of rosuvastatin); (2) Dual therapy (5mg of amlodipine and 10mg of atorvastatin). After 8 weeks of treatment, the change in mean sitting systolic blood pressure (MSSBP) and the percent change in LDL-C between 2 group, will be compared.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
145 mmHg ≤ msSBP ≤ 190 mmHg
Triglycerides \< 500 mg/dL
LDL-C ≤ 250 mg/dL
You may not be if
sSBP ≥ 20mmHg and sDBP ≥ 10mmHg
symptomatic orthostatic hypotension and secondary/iatrogenic hypertension and dyslipidemia
history of moderate to severe cerebral ischemia, cerebral hemorrhage, transient ischemic attack, myocardial infarction, or unstable angina in the past 6 months; severe heart failure (New York Heart Association functional class III and IV)
hypersensitivity to telmisartan or rosuvastatin
history of angioedema after treatment with angiotensin-converting enzyme inhibitors or ARBs; creatinine phosphokinase levels ≥3 times the upper limit of normal
estimated glomerular filtration rate ≤30 mL/min; aspartate aminotransferase and alanine aminotransferase levels ≥3 times the upper limit of normal
potassium levels \>5.5 mmol/L; or any diseases that could affect the results of the study.